Related Experiment Video
Updated: Feb 14, 2026

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Published on: January 12, 2019
Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA2DS2-VASc and HAS-BLED
José Miguel Rivera-Caravaca1, Vanessa Roldán2, María Asunción Esteve-Pastor3
1Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; Department of Hematology and Clinical Oncology, Hospital General Universitario Morales Meseguer, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain.
Insights
The TIMI-AF score showed limited usefulness in predicting net clinical outcomes for atrial fibrillation patients on warfarin. It was not superior to existing CHA2DS2-VASc and HAS-BLED scores in identifying low-risk patients.
Area of Science:
- Cardiology
- Clinical Research
- Pharmacology
Background:
- The TIMI-AF score was developed to predict net clinical outcomes (NCOs) in atrial fibrillation (AF) patients treated with warfarin.
- External validation of the TIMI-AF score in real-world clinical practice is lacking.
- Existing scores like CHA2DS2-VASc and HAS-BLED are used to assess risk in AF patients.
Purpose of the Study:
- To evaluate the long-term predictive performance of the TIMI-AF score.
- To compare the TIMI-AF score with CHA2DS2-VASc and HAS-BLED in a real-world cohort of anticoagulated AF patients.
- To assess the clinical usefulness of the TIMI-AF score in identifying low-risk AF patients.
Main Methods:
- A cohort of 1156 consecutive AF patients stable on vitamin K antagonist (VKA) therapy was included.
- The baseline risk of NCOs (stroke, life-threatening bleeding, all-cause mortality) was calculated using the TIMI-AF score.
- Predictive performance was compared with CHA2DS2-VASc and HAS-BLED during a median follow-up of 6.5 years.
Main Results:
- During follow-up, 563 NCOs occurred (7.49%/year).
- TIMI-AF identified 'low-risk' and 'medium-risk' patients with higher event rates than CHA2DS2-VASc and HAS-BLED.
- The predictive performance of TIMI-AF was not significantly different from CHA2DS2-VASc (0.678 vs 0.677) or HAS-BLED (0.644 vs 0.671).
- TIMI-AF did not improve discrimination, reclassification, or net benefit compared to existing scores.
Conclusions:
- The TIMI-AF score has limited usefulness for predicting NCOs in VKA-experienced AF patients over the long term.
- The TIMI-AF score is not superior to CHA2DS2-VASc and HAS-BLED in identifying low-risk AF patients.
- Further validation and refinement of risk prediction scores for AF patients are warranted.
Abstract:
The TIMI-AF score was described to predict net clinical outcomes (NCOs) in atrial fibrillation (AF) patients receiving warfarin. However, this score derived from the ENGAGE AF-TIMI 48 trial, and no external validation exists in real world clinical practice. We tested the long-term predictive performance of the TIMI-AF score in comparison with CHA2DS2-VASc and HAS-BLED in a 'real-world' cohort of anticoagulated AF patients.
Methods:
We included 1156 consecutive AF patients stable on vitamin K antagonist (INR 2.0-3.0) during 6 months. The baseline risk of NCOs (composite of stroke, life-threatening bleeding, or all-cause mortality) was calculated using the novel TIMI-AF score. During follow-up, all NCOs were recorded and the predictive performance and clinical usefulness of TIMI-AF was compared with CHA2DS2-VASc and HAS-BLED.
Results:
During 6.5 years (IQR 4.3-7.9), there were 563 NCOs (7.49%/year). 'Low-risk' (6.07%/year) and 'medium-risk' (9.49%/year) patients defined by the TIMI-AF suffered more endpoints that low- and medium-risk patients of CHA2DS2-VASc and HAS-BLED (2.37%/year and 4.40%/year for low risk; 3.48%/year and 6.39%/year for medium risk, respectively). The predictive performance of TIMI-AF was not different from CHA2DS2-VASc (0.678 vs 0.677, P = .963) or HAS-BLED (0.644 vs 0.671, P = .054). Discrimination and reclassification did not show improvement of prediction using the TIMI-AF score, and decision curves analysis did not demonstrate higher net benefit.
Conclusions:
In VKA-experienced AF patients, the TIMI-AF score has limited usefulness predicting NCOs over a long-term period of follow-up. This novel score was not superior to CHA2DS2-VASc and HAS-BLED identifying low-risk AF patients.
More Related Videos
Related Concept Videos
Predicting Reaction Outcomes
The Sense of Self: Reflected Self-Appraisal and Social Comparison
Introduction to z Scores
z scores...
Introduction to z Scores
z scores...
z Scores and Area Under the Curve
Predicting Molecular Geometry

